How is maraviroc (MVC) administered in antiretroviral therapy for HIV infection in children?

Updated: Mar 16, 2020
  • Author: David J Cennimo, MD, FAAP, FACP, AAHIVS; Chief Editor: Michelle R Salvaggio, MD, FACP  more...
  • Print
Answer

Answer

Recommended dosage differs based on concomitant medications owing to drug interactions; examples are listed below (ie, not an exhaustive list)

Noninteracting concomitant medications

< 30 kg: Not recommended

≥30 kg: 300 mg PO BID

Noninteracting drugs include tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide

Also, all other medications that are not potent CYP3A inhibitors or inducers

Potent CYP3A inhibitors (with or without a potent CYP3A inducer)

10 kg to < 20 kg: 50 mg PO BID

20 kg to < 30 kg: 75 mg (tablet) or 80 mg (oral solution) PO BID

30 kg to < 40 kg: 100 mg PO BID

≥40 kg: 150 mg PO BID

Potent CYP3A inhibitors include protease inhibitors (except tipranavir/ritonavir), delavirdine, elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin, and other potent CYP3A inhibitors (eg, nefazodone, telithromycin)

Potent CYP3A inducers (without a potent CYP3A inhibitor)

Maraviroc is NOT recommended for children taking potent CYP3A inducers

Potent CYP3A inducers include efavirenz, rifampin, etravirine, carbamazepine, phenobarbital, and phenytoin


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!